statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Veracyte, Inc. (Nasdaq: VCYT) today announced financial results for the first quarter ended March 31, 2024. We had a strong start to 2024, driven by robust growth from our market-leading Decipher...

Veracyte Announces First Quarter 2024 Financial Results

Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that data from 14 presentations at AUA 2024, the annual meeting of the American Urological Association, show that...

14 Studies Presented at AUA 2024 Show Decipher Tests Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding

Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the first quarter of 2024 after the close of market on Tuesday, May 7, 2024. Company management will host a...

Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024

Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that a new study published in JCO Precision Oncology shows that, among patients undergoing Active Surveillance...

New Study Shows Veracytes Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance

Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced that nine abstracts focused on its Decipher Prostate and Decipher Bladder Genomic Classifiers will be presented at...

Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024

For the last three days, A.I.dvisor has detected that VCYT's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

Veracyte (VCYT, $21.64) Aroon Indicator entered a Downtrend on April 01, 2024.

Veracyte, Inc. (NASDAQ:VCYT  Get Free Report) has received an average recommendation of Moderate Buy from the five research firms that are presently covering the stock...

Brokerages Set Veracyte, Inc. (NASDAQ:VCYT) Price Target at $30.00

Veracyte, Inc. (NASDAQ:VCYT  Get Free Report) has been given a consensus recommendation of Moderate Buy by the five ratings firms that are currently covering the company...

Veracyte, Inc. (NASDAQ:VCYT) Receives $30.00 Average Target Price from Brokerages

Veracyte (VCYT, $22.12) Aroon Indicator entered a Downtrend on March 28, 2024.

This is a signal that VCYT's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...

Veracyte (VCYT, $21.72) Stochastic Oscillator left the oversold zone on March 27, 2024

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Watchers	1,124
52-Wk Low	$18.61
52-Wk High	$30.52

Volume	746,995.00
52-Wk High	$30.52
52-Wk Low	$18.61

VCYT Veracyte Inc

About

Feed

News

Sentiment

Earnings

Fundamentals